EGFR and non-small cell lung carcinoma: It has been reported that the response to prior EGFR-TKI was associated with the outcomes of subsequent immunotherapy remains: for NSCLC patients with T790 M mutation, patients with short TKI-PFS conferred better response to immunotherapy than those with long.[17] Thus, the PFS is as short as about 3 months after second-line immunotherapy combined with chemotherapy treatment, possibly suggesting that patient carrying D761Y mutation not only present with a poorer prognosis than other EGFR mutations but also has association with the outcome of subsequent immunotherapy.